NCT03705806Active, not recruiting
Palliative Thoracic ImmunoRT
Evaluation of Toxicities With Thoracic Radiotherapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 12 (actual)
- First submitted
- 15 Aug 2018
- Start date
- 3 Oct 2018
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Lung cancer
- NCT number
- NCT03705806
What you commit to
- Study type: Observational
- Participants enrolled: 12
- From 3 Oct 2018 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of thoracic radiotherapy with an overlapping field
- Previous history of checkpoint inhibitor related pneumonitis or esophagitis
Other illness
- Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia
Other
- Pregnancy
Who the study is looking for
- Pathologically confirmed AJCC 7th/8th edition Stage IV adenocarcinoma or squamous cell carcinoma not eligible for curative treatment.
- Indication and suitability to receive palliative radiotherapy to the thorax (30Gy/10).
- Receiving or planned to receive nivolumab or pembrolizumab
- Prior history of systemic chemotherapy is permitted given a washout period of 4 weeks
- Age 18 or older
- ECOG Performance Status 0-2
- Life expectancy greater than 3 months
- Able and willing to provide informed consent
- Able to complete patient reported outcome questionnaires
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network - Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.